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WAFJ/CIPJ structural abnormalities do not contribute to cell cycle
deregulation in ovarian cancer
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Summary Mutations in the WAFJ/CIPJ gene were not found in 36 ovarian carcinomas, including tumours
with loss of heterozygosity at the WAFJ/CIPI locus and/or lacking p53 mutations. In addition, no association
was demonstrable between a polymorphism in a conserved region of the WAFI/CIPI gene and ovarian
carcinoma
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The p21 protein is a cyclin-dependent kinase (CDK) inhibitor
encoded by the WAFI/CIP1 gene (Harper et al., 1993; Xiong
et al., 1993; El-Deiry et al., 1993). It is a mediator of p53 (El-
Deiry et al., 1993, 1994), a tumour-suppressor gene mutated
in a wide variety of tumours (Hollstein et al., 1991). It
provides a link between cell cycle regulation and p53
expression, as its induction by p53 results in inhibition of
cyclin/CDK-mediated phosphorylation of retinoblastoma
(RB) protein. The latter is required for GI to S transition
(Harper et al., 1993; El-Deiry et al., 1993). WAFJ/CIPI may
have additional roles in cell cycle regulation and cancer
because it can also be induced by a p53-independent pathway
(Michieli et al., 1994) and is able to inhibit DNA replication
and repair independently of the CDKs (Waga et al., 1994; Li
et al., 1994).
It was proposed that mutations in the WAFI/CIPI gene
may contribute to the development of ovarian tumours
lacking p53 mutations (El-Deiry et al., 1993), as these
tumours frequently show losses of heterozygosity in a region
of chromosome 6p that includes the WAFJ/CIP] locus (Cliby
et al., 1993; Foulkes et al., 1993; Wan et al., 1994). A
tumour-suppressor role for p21 is further supported by the
fact that its expression inhibits the growth ofcultured tumour
cells (El-Deiry et al., 1993). The finding of point mutations in
ovarian tumours with loss of heterozygosity involving the
WAFJ/CIP1 locus, especially in the absence of p53
mutations, would strongly support a role for this gene as a
tumour suppressor important for the control of ovarian
tumorigenesis. We therefore sequenced the WAFJ/CIP1 gene
in ovarian tumours already characterised for the presence or
absence of loss of heterozygosity at this locus and for p53
mutations.
Materials and methods
Source and handling of tissue and blood samples
All tumours were of ovarian epithelial origin. The source and
handling procedures were described previously (Wan et al.,
1994). DNA from normal individuals was extracted from
white blood cells obtained from volunteers of mixed ethnic
origins but with a predominance of those of Hispanic origin.
Mutational analysis of WAF1/CIPI gene
The entire exon 2 and the 5' portion of exon 3 of the WAFII
CIP] gene were enzymatically amplified from genomic DNA
using intron-based primers (obtained from Dr Bert Vogel-
stein, Baltimore, MD, USA). The sense and antisense primers
used for amplification of exon 2 were 5'-TGGAAGGAGT-
GAGAGAGA-3' and 5'-ATCCTGGTCCCTTACAAAGT-3'
respectively. Sense and antisense primers for amplification of
the 5' portion of exon 3 were 5'-GGCAGCTCCGCCGC-
GTCC-3' and 5'-CGCGCTTCCAGGACTGCAGG-3'. The
amplification products from exon 3 were reamplified using
the following sense nested primer: 5'-CTTCTTGGCCTGG-
CTGAC-3'. Annealing temperatures were 1°C below the
lowest primer melting temperature, as calculated using Gene
Jockey software (Biosoft, Cambridge, UK, version 1.20). The
PCR products were electrophoresed on 1% agarose gels. The
resulting bands were excised, purified using a Qiaex Kit
(Qiagen, Chatsworth, CA, USA), and sequenced directly
using the Sequenase 2.0 Kit (US Biochemicals, Cleveland,
OH, USA) following protocols recommended by the
manufacturers. The products were electrophoresed on 6%
polyacrylamide gels under denaturing conditions. The sense
primers used for direct sequencing of enzymatically amplified
exon 2 were: 5'-CGCCATGTCAGAACCG-3', 5'-ATGGA-
ACTTCGACTTTGTCA-3' and 5'-AAGACCATGTGGAC-
CTGTCA-3'. Antisense sequencing primers for exon 2 were:
5'-GTCATGCTGGTCTGCCGCCG-3', 5'-AAGTCACCCT-
CCAGTGGTGT-3' and 5'-AGACAGTGACAGGTCCA-
CAT-3'. The exon 3 amplification primers were also used as
sequencing primers for this exon.
Loss of heterozygosity determinations and documentation of
p53 mutations
Loss of heterozygosity and p53 mutation analyses were
reported previously in these tumour samples (Wan et al.,
1994; Zheng et al., 1995).
Statistical analyses
Differences between two proportions were calculated using
Fisher's exact test. All P-values are double-sided.
Results
We sequenced the entire coding region of the WAFI/CIPJ
gene in 36 ovarian carcinomas. Such mutations were not
found in any of these tumours, which included 18 carcinomas
not harbouring any p53 mutations and 14 with loss of
heterozygosity on chromosome 6p (Table I). A single
nucleotide substitution, involving codon 31 of the WAFI/
CIPI gene (AGC to AGA), was observed in 12 (33%)
tumours (Table I). This substitution, changing the predicted
amino acid from serine to arginine, was concordant in the
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Table I Absence of WAFI/CIPI mutations in 36 ovarian tumours characterised for the presence or absence of loss of
heterozygosity (LOH) on chromosome 6p and ofp53 mutations
WAFI/CIPI Codon 31
Case no. p53 mutation LOH on 6p mutation allele
10 CGT to GGT (codon 273) No None Ser
12 None detected No None Ser
15 None detected Yes None Ser
16 ATC to ACC (codon 232) No None Ser
24 GCC to CCC (codon 138) Yes None Ser
30 None detected No None Arg
31 CGT to CAT (codon 273) Yes None Ser
33 CGC to CAC (codon 175) No None Arg
41 CGT to CAT (codon 273) No None Ser
43 None detected No None Arg
44 None detected No None Arg
47 TGC to TGG (codon 176) GAG to GAC (codon 271) Yes None Ser
49 None detected Yes None Ser
51 Loss of A (codon 209) Yes None Ser
53 Immunopositivea No None Ser
54 None detected No None Arg
55 None detected No None Ser
57 None detected No None Ser
59 Immunopositive No None Ser
61 None detected No None Ser
62 None detected No None Ser
63 GTG to TTG (codon 173) Yes None Arg
64 AGA to ATA (codon 209) No None Arg
67 None detected Yes None Ser
69 CGG to GGG (codon 248) Yes None Ser
71 Immunopositive Yes None Arg
72 None detected Yes None Arg
73 Immunopositive No None Ser
74 GTG to ATG (codon 272) Yes None Set
76 None detected Yes None Ser
78 None detected No None Arg
84 None detected No None Ser
87 None detected No None Ser
92 TGC to TTC (codon 242) Yes None Arg
97 CGG to TGG (codon 248) No None Arg
98 None detected No None Ser
aTumour with no detectable p53 mutation based on DNA sequencing studies but showing immunopositivity with anti-p53
antibody (Zheng et al., 1995).
patients' normal cells and therefore constitutes a polymorph-
ism rather than a mutation, in agreement with Chedid et al.
(1994). Six of the 12 cases showing this polymorphism
contained p53 mutations and four showed loss of hetero-
zygosity on chromosome 6p. Thus, there was no correlation
between presence of the polymorphism and either p53
mutations (P= 1.3) or allelic loss on chromosome 6p
(P=0.7). We sequenced 27 blood DNA samples obtained
from normal individuals to determine whether this poly-
morphism was associated with increased cancer predisposi-
tion. The Arg3l allele was found in 10 of the 27 (37%)
normal individuals, indicating that its frequency in the
normal population was not different from that of patients
with ovarian carcinomas (P=0.8).
Discussion
The results of our experiments clearly show that WAFJ/CIPI
mutations are rare in ovarian carcinomas, including those
tumours with allelic losses at the WAFJ/CIP1 locus and those
tumours without p53 mutations. These results are therefore
not compatible with the idea that mutational inactivation of
the WAFJ/CIPI gene is important for the control of ovarian
tumorigenesis. Recently published studies (Shiohara et al.,
1994; Li et al., 1995; Marchetti et al., 1995; Mousses et al.,
1995) also failed to detect any mutational inactivation of the
WAFJ/CIPI gene in different tumour types, including
ovarian carcinomas. Thus, WAFI/CIPI mutations may not
constitute an important mechanism of tumour development
in general, in spite of the fact that this gene is a downstream
mediator of p53 activity.
The absence of WAFJ/CIP1 mutations in ovarian tumours
with losses ofheterozygosity on chromosome 6p suggests that
such losses may target a separate tumour-suppressor gene on
this chromosome. Another possibility is that partial loss of
WAFJ/CIPJ activity or expression, either through unilateral
allelic deletions or other mechanisms, may be sufficient to
contribute to tumour development. In that regard, we tested
the hypothesis that a recently described sequence polymorph-
ism in the WAFJ/CIPJ gene could be associated with ovarian
carcinoma predisposition. We reasoned that this polymorph-
ism could result in significant alterations in WAFJ/CIPJ
activity because it affects a conserved region of the gene and
results in a major change in the predicted amino acid
sequence (serine to arginine). However, there was no
detectable difference in the frequencies of this polymorphism
when patients with ovarian carcinomas were compared with a
group of normal individuals. Likewise, there was no
association between the presence of the variant allele and
either p53 mutations or loss of heterozygosity on chromo-
some 6p. These results differ from those of Mousses et al.
(1995), who observed an increased frequency of the variant
allele in tumours without p53 mutations as well as a decrease
in the frequency of this allele in tumours with p53 mutations.
The reasons for these apparent discrepancies are not clear.WAFl/CIPI mutation in ovarian carcinas
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One possibility is that these authors studied different tumour
types including tumours of mesench-mal origin but did not
examine ovarian carcinomas. In addition. it is not known if
the p53 mutations that they examined were similar to those
present in our tumour population.
There is growing e'vidence supporting the notion that
derangements in cell cycle control play an important role in
tumour development (Hartw-ell and Kastan. 1994: Hunter.
1993). Further evidence for such derangements in ovarian
tumours comes from the apparent constituti've expression of
the RB gene in these tumours (Kim et al.. 1994: Dodson et
al.. 1994). Mutations in the p53 gene. which are frequent in
ov-arian tumours (Zheng et al.. 1995). may account for such
expression in some cases. Structural abnormalities in one or
se,veral other mediators of cell cycle activity must be present
in the remaining cases. However. mutations in the RB gene
itself are infrequent in these tumours (Kim et al.. 1994:
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